Australia markets closed

Cullinan Therapeutics, Inc. (CGEM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.30+0.72 (+2.61%)
At close: 04:00PM EDT
28.35 -0.00 (-0.01%)
Pre-market: 09:05AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.22B
Enterprise value 757.43M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.69
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.98

Trading information

Stock price history

Beta (5Y monthly) 0.33
52-week change 3190.01%
S&P500 52-week change 322.38%
52-week high 329.25
52-week low 37.64
50-day moving average 318.12
200-day moving average 312.50

Share statistics

Avg vol (3-month) 3694.38k
Avg vol (10-day) 31.71M
Shares outstanding 543.07M
Implied shares outstanding 643.07M
Float 822.59M
% held by insiders 16.40%
% held by institutions 1102.50%
Shares short (15 Apr 2024) 41.68M
Short ratio (15 Apr 2024) 44.41
Short % of float (15 Apr 2024) 44.79%
Short % of shares outstanding (15 Apr 2024) 43.90%
Shares short (prior month 15 Mar 2024) 4935.41k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.80%
Return on equity (ttm)-31.37%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -190.34M
Net income avi to common (ttm)-153.16M
Diluted EPS (ttm)-3.69
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)467.07M
Total cash per share (mrq)10.85
Total debt (mrq)3.59M
Total debt/equity (mrq)0.79%
Current ratio (mrq)17.07
Book value per share (mrq)10.58

Cash flow statement

Operating cash flow (ttm)-134.28M
Levered free cash flow (ttm)-88.76M